On August 4, 2022, bluebird bio, Inc. appointed TOM KLIMA, 50, as Chief Commercial & Operating Officer – Effective August 8, 2022. Klima joined bluebird in May 2021 as Chief Commercial officer to hone the Company's commercial strategy and oversee launch execution plans for its gene therapy portfolio. His new role reflects expanded responsibilities for program management and patient supply chain in addition to sales, marketing and market access.

Prior to joining bluebird bio, Mr. Klima served as Chief Commercial Officer at Gamida Cell Ltd. from January 2019 to December 2020, where he led the strategic vision and commercial growth transforming its R&D organization to a commercially ready company. In 2018, Mr. Klima served as senior vice president of global commercial planning and operations at Atara Biotherapeutics. From 2015 to 2017, Mr. Klima served as senior vice president and chief commercial officer at Navidea Biopharmaceuticals Ltd. (acquired by Cardinal Health).

Mr. Klima received a B.A. in Business Administration and Marketing from Western State College.